siRNA sequence and method for treating dengue virus infection

Case ID:
Web Published:

siRNA sequence and method for treating dengue virus infection

OHSU Technology 1601


Value Proposition:

Dengue virus (DENV) is a leading cause of illness in the tropics and subtropics, with as many as 100 million people infected yearly. Currently, there is no approved vaccine for DENV or any approved antiviral compositions to treat DENV either prophylactically or therapeutically, and no approved single agent that has demonstrated efficacy against infection by all four DENV serotypes. Researchers in the Vaccine and Gene Therapy Institute at Oregon Health & Science University have discovered a novel siRNA which represents the first reported composition to show in vitro activity against strains from each of the 4 DENV serotypes and in vivo activity against a lethal DENV-2 infection in mice.


Technology Overview:

More than onethird of the world’s population lives in areas at risk for transmission of dengue virus.  Dengue virus is a flavivirus, in the same genus as West Nile virus and Yellow Fever virus. Dengue is caused by any one of four related viral serotypes (DENV1, DENV2, DENV3, and DENV4), all of which are transmitted by mosquitoes.  Any of the four serotypes can cause severe disease in humans and all four serotypes circulate globally. This sequence variability makes development of both vaccines and compositions for the treatment of dengue very difficult. Because treatment of dengue disease must occur very rapidly after symptoms develop, a composition used in the treatment of dengue disease must work against all four serotypes of dengue. A pharmaceutical composition that works against less than all serotypes would not be a fully effective therapeutic because it could require a serotype identification test prior to treatment. A serotype identification would delay treatment at best and could be unavailable in areas in which dengue is endemic. Similarly, a pharmaceutical composition that works against fewer than all serotypes would be ineffective as a prophylactic treatment due to the fact that all four serotypes circulate throughout the world. Here we report a single siRNA composition that has great potential to meet this unmet medical need.


Basic Market Information/Competitive Environment:

Hundreds of thousands of clinical dengue disease cases are reported by clinicians annually to the WHO and dengue disease has a mortality rate of 0.5% to 5.0%.


Inventor Profile:

Klaus Früh, Professor and Senior Scientist at OHSU is applying the tools of functional genomics – chemogenomics, transcriptomics, proteomics, interactomics and small interfering RNA - to search in a systematic fashion for host targets that are modified during infection by Dengue virus and related flaviruses such as West Nile Virus.  


Patent Status

Technology 1601 – Patent Filed, PCT US/2012/47000


Licensing Opportunity

Technology 1601 is available for exclusive licensing and/or collaborative co-development.


Relevant Publication

Früh, K et al., 2011, Inhibition of Dengue Virus Infections in Cell Cultures and in AG129 Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence, J. Virol. 85(19):10154-10166.

Patent Information:
For Information, Contact:
Travis Cook
Senior Technology Development Manager
Oregon Health & Science University
David Stein
Klaus Frueh
Stuart Perry
Sujan Shresta
Research Tools - Reagents
Therapeutics - Infectious Diseases
© 2022. All Rights Reserved. Powered by Inteum